The decision came after the European Medicines Agency (EMA), the drug regulator of the European Union (EU), recommended the use of the Nuvaxovid vaccine produced against COVID-19.
In a written statement from WHO, it was stated that following the EMA’s statement, the emergency use of the Nuvaxovid vaccine was approved.
In the statement, it was noted that the Nuvaxovid vaccine is the joint work of the US pharmaceutical company Novavax and the Innovation Coalition for Epidemic Preparedness (CEPI) and is the “original product” of the Covovax vaccine produced in India, which was approved for emergency use on 17 December.
It was stated in the statement that both vaccines are produced using one-to-one technologies, and that Nuvaxovid and Covovax are protected at 2 to 8 degrees Celsius.
18 age limit has been brought
In the statement made by EMA, it was reported that the vaccine named “Nuvaxovid” can be used in people over the age of 18.
It was stated that the protein-based vaccine, which was administered in two doses for three weeks, was approximately 90 percent effective against the disease in studies conducted on 45 thousand people.
EMA has so far approved the use of vaccines produced by Pfizer/Biontech, Moderna, AstraZeneca, Johnson and Johnson and Novavax, and drugs called Kineret, Regkirona, Roactemra, Ronapreve, Veklury and Xevudy.
Emergency use approval for 10 vaccines
With this decision, WHO has approved the 10th COVID-19 vaccine for emergency use.
WHO, firstly on December 31, 2020, on the COVID-19 vaccine produced by Pfizer-BioNTech, then Oxford-AstraZeneca, the vaccine produced by the Indian Serum Institute (SII), the vaccine manufacturer of AstraZeneca, Moderna, Janssen and China. It gave emergency use approval to the vaccines produced by the Sinopharm company.
The organization announced that the new Sinovac vaccine developed by China, which was also used in Turkey on June 1, 2021, the Covaxin vaccine produced in India on November 3, 2021, and finally the vaccine of Covovax, which was produced in India again on December 17, 2021. It was approved for immediate use.